Zacks Investment Research downgraded shares of Calithera Biosciences, Inc. (NASDAQ:CALA) from a buy rating to a hold rating in a research report released on Tuesday morning.

According to Zacks, “Calithera Biosciences, Inc. is a clinical-stage pharmaceutical company. It is focused on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. The Company’s lead product candidate includes CB-839 which is in three Phase I clinical trials for the treatment of patients with solid tumors, leukemias, lymphomas, and multiple myeloma. Calithera Biosciences, Inc. is headquartered in South San Francisco, California. “

A number of other equities research analysts have also recently weighed in on the company. Citigroup Inc. began coverage on Calithera Biosciences in a report on Tuesday, October 25th. They set a sell rating for the company. JMP Securities reaffirmed a buy rating on shares of Calithera Biosciences in a report on Thursday, November 10th. Finally, HC Wainwright began coverage on Calithera Biosciences in a report on Thursday, January 5th. They set a buy rating and a $9.00 price target for the company. One research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. Calithera Biosciences currently has an average rating of Buy and a consensus target price of $9.19.

Analyst Recommendations for Calithera Biosciences (NASDAQ:CALA)

Shares of Calithera Biosciences (NASDAQ:CALA) traded down 2.20% during mid-day trading on Tuesday, hitting $4.45. The stock had a trading volume of 156,536 shares. Calithera Biosciences has a 12-month low of $2.20 and a 12-month high of $6.87. The firm’s 50-day moving average price is $3.41 and its 200 day moving average price is $3.24. The stock’s market cap is $92.28 million.

COPYRIGHT VIOLATION WARNING: “Calithera Biosciences, Inc. (CALA) Downgraded by Zacks Investment Research to “Hold”” was posted by The Cerbat Gem and is the propert of of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and reposted in violation of international trademark & copyright law. The original version of this article can be accessed at https://www.thecerbatgem.com/2017/01/11/calithera-biosciences-inc-cala-downgraded-by-zacks-investment-research-to-hold.html.

In other news, major shareholder Adage Capital Partners Gp, L.L bought 500,000 shares of the stock in a transaction dated Wednesday, November 16th. The stock was bought at an average cost of $3.15 per share, with a total value of $1,575,000.00. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. 27.50% of the stock is owned by insiders.

Several large investors have recently added to or reduced their stakes in the stock. First Eagle Investment Management LLC boosted its stake in Calithera Biosciences by 162.0% in the third quarter. First Eagle Investment Management LLC now owns 538,103 shares of the company’s stock valued at $1,749,000 after buying an additional 332,734 shares during the period. Bridgeway Capital Management Inc. boosted its stake in Calithera Biosciences by 102.8% in the second quarter. Bridgeway Capital Management Inc. now owns 157,850 shares of the company’s stock valued at $586,000 after buying an additional 80,000 shares during the period. Franklin Street Advisors Inc. NC boosted its stake in Calithera Biosciences by 18.6% in the third quarter. Franklin Street Advisors Inc. NC now owns 100,000 shares of the company’s stock valued at $325,000 after buying an additional 15,700 shares during the period. D. E. Shaw & Co. Inc. boosted its stake in Calithera Biosciences by 119.1% in the third quarter. D. E. Shaw & Co. Inc. now owns 81,613 shares of the company’s stock valued at $265,000 after buying an additional 44,364 shares during the period. Finally, GSA Capital Partners LLP boosted its stake in Calithera Biosciences by 25.9% in the second quarter. GSA Capital Partners LLP now owns 43,800 shares of the company’s stock valued at $162,000 after buying an additional 9,000 shares during the period. 40.23% of the stock is owned by institutional investors.

About Calithera Biosciences

Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.

5 Day Chart for NASDAQ:CALA

Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.